Key points from article :
UK regulators have approved a gene therapy called Casgevy to treat sickle cell disease and beta thalassemia.
Casgevy is the first drug to be MHRA-licensed using the gene-editing tool CRISPR.
CRISPR allows for the precise manipulation of DNA to correct genetic defects.
Casgevy involves removing bone marrow stem cells from a patient and using CRISPR to edit the cells' DNA.
The modified cells are then infused back into the patient, allowing them to produce healthy hemoglobin.
In trials, Casgevy was found to be effective in treating both sickle cell disease and beta thalassemia.
The drug is personalized for each patient, which makes it expensive and time-consuming to produce.
The price of Casgevy has not yet been set, but it is likely to be high.